Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET ENCORE-UC
jRCT2031260126Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing JNJ-78934804 with Guselkumab (2 arms). Primary endpoint: Percentage of participants in clinical remission at Week 48. Started Jun 2026; status: recruiting.
02
Drugs
guselkumab + golimumabguselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031260126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260126.